预约演示
更新于：2026-02-27
Dolutegravir Sodium/Lamivudine
多替拉韦钠/拉米夫定
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H30F2N6NaO8S |
InChIKeyYZPUFLUMGTVLTO-JQRDVGSASA-N |
CAS号2446159-49-3 |
关联
51
项与 多替拉韦钠/拉米夫定 相关的临床试验NCT07393659
A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.
开始日期2026-05-08 |
申办/合作机构 |
CTR20253858
拉米夫定多替拉韦片（300mg/50mg）在健康受试者中随机、开放、两制剂、单次给药、两周期、两序列餐后状态下的生物等效性试验
主要目的：以海南林依生物科技有限公司的拉米夫定多替拉韦片（规格：拉米夫定300mg/多替拉韦钠50mg（以多替拉韦计））为受试制剂，按生物等效性试验的有关规定，与持证商ViiV Healthcare BV公司的拉米夫定多替拉韦片（规格：拉米夫定300mg/多替拉韦钠50mg（以多替拉韦计），商品名：多伟托®）对比餐后状态下在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。
次要目的：观察餐后状态下受试制剂拉米夫定多替拉韦片（300mg/50mg）和参比制剂拉米夫定多替拉韦片（300mg/50mg）（商品名：多伟托®）在健康受试者中的安全性。
开始日期2025-09-29 |
申办/合作机构 |
NCT06497465
Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral naïve People With HIV and TB Receiving Rifampin-based TB Treatment
This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or DTG/3TC ( Dovato) in the morning +dolutegravir (DTG) in the evening, versus standard of care (SOC) twice-daily dolutegravir plus 2 once-daily Nucleoside reverse-transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate /lamivudine (TDF/3TC), among antiretroviral therapy (ART)-nave individuals with HIV-1 receiving rifampin-based TB therapy
开始日期2025-09-18 |
申办/合作机构 |
100 项与 多替拉韦钠/拉米夫定 相关的临床结果
登录后查看更多信息
100 项与 多替拉韦钠/拉米夫定 相关的转化医学
登录后查看更多信息
100 项与 多替拉韦钠/拉米夫定 相关的专利（医药）
登录后查看更多信息
13
项与 多替拉韦钠/拉米夫定 相关的文献（医药）2026-01-01·INTERNATIONAL JOURNAL OF STD & AIDS
Acute rhabdomyolysis in a woman living with HIV - antiretroviral treatment is not always to blame
Article
作者: Risser, Clémence ; Dubois, Maxime ; Ursenbach, Axel ; Probst, Léa ; Rey, David ; Groza, Monica ; Bernard-Henry, Claudine
We report a 49-year-old woman living with HIV who stopped her antiretroviral treatment for several weeks. One month after resuming treatment with dolutegravir and lamivudine (Dovato
®
), she presented with myalgia, physical weakness and rhabdomyolysis. As we suspected a drug-related cause, Dovato
®
was changed for tenofovir disoproxil fumarate, lamivudine and doravirine (Delstrigo
®
) without improvement. Second line assessment led to a diagnosis of dermatomyositis, with presence of anti-Mi-2 antibodies, typical MRI findings and pathological analysis of muscle biopsy. The outcome was favorable after treatment with corticosteroids followed by methotrexate. Dovato
®
was subsequently re-prescribed without recurrence of symptoms or rhabdomyolysis.
2025-10-01·Therapeutic Advances in Infectious Disease
Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study
Article
作者: Marcellin, Fabienne ; Brown Hajdukova, Eva ; Chassany, Olivier ; Alain, Tristan ; Duracinsky, Martin ; Hocqueloux, Laurent ; Rousset Torrente, Olivia ; Zucman, David ; Allavena, Clotilde
Background::
Simplification of antiretroviral regimens has the potential to improve both patient-reported outcomes (PROs) and therapeutic adherence in people living with HIV (PLWH). Dual therapy with dolutegravir (DTG) plus lamivudine (3TC) demonstrated good safety and efficacy, but its impact on PROs remains to be documented.
Objectives::
To evaluate PROs among adult PLWH switching from standard multi-drug therapy to the DTG/3TC combined therapy Dovato
®
.
Design::
A non-comparative, 6-month observational study in 25 French medical centers.
Methods::
Sociodemographic and biomedical data were collected from medical records and PROs from self-administered questionnaires at treatment switch (Day, D0) and at months (M) 1 and 6. Primary endpoints included changes between D0 and M6 in perceived toxicity, treatment acceptability, PLWH’s preferences, and the score value of the treatment impact dimension of health-related quality of life (HRQL) (PROQOL-HIV) during follow-up. Secondary endpoints encompassed scores in other HRQL dimensions and self-reported symptoms. Multivariable standard and mixed-effects linear regression models were used to identify factors associated with PRO values and changes over time. Additionally, binary logistic regression was used to identify factors associated with the discontinuation of combined DTG/3TC regimen.
Results::
In the study population (260 PLWH, 64.6% male, mean ± SD age: 51 ± 12 years, 16 ± 10 years since HIV diagnosis), 20 individuals stopped treatment during follow-up, without resumption. Men, individuals previously receiving abacavir/3TC/DTG, and those with better daily comfort and perceived treatment efficacy were less likely to stop treatment. Treatment impact-related HRQL, acceptability of treatment, and number of self-reported symptoms significantly improved at M1 and M6. Mental and cognitive HRQL improved at M6.
Conclusion::
Dolutegravir and lamivudine dual oral therapy improved several dimensions in HRQL and delivered a simplified treatment regimen designed for eligible patients, supporting a patient-centered approach to managing HIV care. Attention should be maintained on the reasons for treatment discontinuation, especially among women.
Trial registration::
Patient-Reported Outcomes HV BItherapy (PROBI) was registered as number NCT04788784 on
https://clinicaltrials.gov/study/NCT04788784?term=PROBI&rank=2
.
2025-04-21·Cureus Journal of Medical Science
A Stable Switch From Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) to Dolutegravir/Lamivudine (DTG/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort
Article
作者: Fallon, James P ; Borsi, Rebecca A ; Touza, Masara ; Slim, Jihad ; Bellafiore, Paul
OBJECTIVE:
This article aims to examine the safety and efficacy of switching from bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) to dolutegravir and lamivudine (DTG/3TC) in the absence of prior resistance records.
DESIGN:
Switch to Dovato in patients suppressed on Biktarvy (SOUND) is an open-label, single-arm, pilot study of adult people with HIV who were virologically suppressed (HIV-1 <50 copies/mL) on B/FTC/TAF for >24 weeks, and switched to DTG/3TC in the absence of available resistance records.
METHODS:
The primary endpoint was the percentage of participants with HIV viral load (VL) ≥50 c/mL at week 48. Secondary endpoints at weeks 48 and 96 included the percentage of participants with HIV-VL <50 c/mL, incidence and severity of adverse events, laboratory abnormalities, change in baseline CD4 cell count, and retrospective proviral DNA resistance testing on banked baseline samples.
RESULTS:
Of the 40 individuals enrolled, 0% had VL ≥50 c/mL at week 48. No participants discontinued due to laboratory abnormalities or safety-related concerns. Three participants withdrew from the study while virologically suppressed. Among the 32 baseline samples available for retrospective proviral DNA resistance testing, six (19%) had nucleoside reverse transcriptase inhibitor resistance-associated mutations (RAMs), all with M184V. Two (6%) participants had integrase strand transfer inhibitor RAMs at baseline (S147S/G and Q148Q/R); neither conferred resistance to DTG. Nonnucleoside reverse transcriptase inhibitor and protease inhibitor RAMs were observed in eight (25%) and three (9%) participants, respectively. A significant decrease in weight was observed over the study period.
CONCLUSIONS:
Results from SOUND support the efficacy and safety of switching to DTG/3TC for people living with HIV-1 who are virologically suppressed on B/FTC/TAF with unknown resistance history and may confer a weight advantage.
132
项与 多替拉韦钠/拉米夫定 相关的新闻（医药）2026-02-26
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
2026-02-26
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
2026-02-25
最近GSK出手比较多了。一、核心结论
2026年2月25日，葛兰素史克（GSK）宣布以9.5亿美元全现金收购加拿大临床阶段生物制药公司35Pharma Inc.，获得其核心资产——HS235（一款具有“同类最佳”潜力的激活素信号抑制剂），旨在强化心血管代谢疾病管线，尤其是肺动脉高压（PH）领域的治疗布局。这笔交易是GSK新任CEO卢克·米尔斯（Luke Miels）上任以来第二笔重大收购，也是其对“肥胖下游疾病”（如心肺疾病）战略的持续推进。二、交易基本信息
收购方：葛兰素史克（GSK，伦敦证券交易所代码：GSK；纽约证券交易所代码：GSK）
被收购方：35Pharma Inc.（加拿大私人持有临床阶段生物制药公司，专注于TGF-β超家族疗法开发）
交易金额：9.5亿美元（全现金支付）
交易标的：35Pharma全部股权，包括其核心管线HS235及相关技术平台
交易进展：已签署协议，待获得美加监管批准（如美国《哈特-斯科特-罗迪诺法案》、加拿大《竞争法》）后即可完成。三、核心资产HS235：差异化设计的“同类最佳”候选药物
HS235是35Pharma的核心管线，属于激活素/GDF decoy trap（激活素/生长分化因子诱饵陷阱），针对肺动脉高压（PAH）和射血分数保留心衰相关肺高压（PH-HFpEF），目前已进入I期临床试验后期，即将启动II期临床研究。其核心价值在于差异化设计与多重获益：1. 靶点机制：精准抑制病理信号，保留生理功能
HS235靶向激活素受体信号通路（PAH治疗的临床验证靶点），但通过理性分子设计，选择性保留BMP-9/-10配体活性（这两种配体是维持血管和淋巴系统完整性的关键）。相比之下，现有激活素抑制剂（如默沙东的sotatercept）因非选择性抑制BMP-9/-10，易导致出血、毛细血管扩张等副作用。HS235的设计有望解决这一痛点，提高安全性。2. 临床前/早期临床数据：代谢与心肺保护的“双赢”
安全性：I期健康志愿者试验显示，HS235耐受性良好，未出现严重不良事件。
有效性：临床前研究（如肥胖HFpEF小鼠模型）表明，HS235可逆转心肌肥厚、减少内脏脂肪（尤其是腹部脂肪）、增加肌肉质量（瘦体重），并改善胰岛素敏感性。这些数据提示，HS235不仅能治疗肺高压，还能改善患者合并的肥胖、胰岛素抵抗等代谢问题。
协同效应：HS235与GLP-1类药物（如诺和诺德的司美格鲁肽）有潜在协同作用——GLP-1可减少体重，但可能导致肌肉流失，而HS235能保护甚至增加瘦体重，两者联用有望成为心血管代谢疾病的“组合拳”。四、战略意图：GSK对心血管代谢疾病的精准布局
此次收购是GSK呼吸、免疫与炎症（RI&I）管线的关键补位，符合其“聚焦肥胖下游疾病”的战略方向（如肝脏、心脏疾病），具体意图包括：1. 强化心肺疾病管线，填补“血管重塑”空白
GSK在呼吸领域已有depemokimab（超长效抗IL-5，用于嗜酸性粒细胞性哮喘）等后期资产，但缺乏针对“血管重塑”（如肺高压）的药物。HS235的加入，使GSK的管线从“炎症抑制”延伸至“血管调节”，覆盖了从气道到肺血管的完整呼吸疾病谱系。2. 差异化竞争，抢占激活素抑制剂赛道
全球肺高压患者约8200万，五年生存率仅约50%，相关治疗药物市场预计到2032年将达到180亿美元（激活素信号抑制剂占50%）。GSK在HS235仅完成I期试验时就出手收购，正是看准了这一细分赛道的爆发潜力，意图在竞争格局未定之时锁定“同类最佳”资产。3. 应对专利到期压力，补充新药储备
GSK的支柱性HIV药物（如Dovato）将在2028年前后专利到期，新任CEO卢克·米尔斯需通过收购补充新药储备，抵消专利悬崖的影响。此次收购HS235，是其在心血管代谢领域的重要布局，有望成为未来的增长引擎。五、后续关注要点
监管审批：交易需通过美国和加拿大的反垄断审查，预计将在2026年下半年完成。
临床进展：HS235即将启动II期临床研究（针对PAH和PH-HFpEF），其结果将验证其疗效和安全性，是关键节点。
与现有疗法的对比：未来需开展头对头试验，比较HS235与默沙东sotatercept的疗效（如运动耐量、肺血管阻力）和安全性（如出血风险）。
联用开发：GSK可能与减肥药巨头（如诺和诺德、礼来）合作，探索HS235与GLP-1类药物的联用，拓展心血管代谢疾病的应用场景。六、总结
GSK收购35Pharma，本质是对“心血管代谢疾病下一代疗法”的押注——HS235不仅是一款肺高压药物，更是“代谢调节+心肺保护”的组合型疗法。其差异化设计（保留BMP-9/-10）和多重获益（减脂、保肌、改善胰岛素抵抗），使其在现有疗法中具有明显优势。若HS235能在后续临床中兑现承诺，将成为GSK RI&I管线中的核心资产，甚至改写肺高压治疗格局。
此次交易也反映了跨国药企对“肥胖下游疾病”的重视——随着GLP-1类药物的普及，患者对“减重+并发症管理”的需求日益增长，GSK通过收购HS235，提前卡位这一赛道，有望在未来的竞争中占据主动。
100 项与 多替拉韦钠/拉米夫定 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2019-04-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺结核 | 临床3期 | 巴西 | 2025-09-18 | |
| 结核 | 临床3期 | 巴西 | 2025-09-18 | |
| HIV血清阳性 | 临床3期 | 美国 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 日本 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 澳大利亚 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 比利时 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 加拿大 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 法国 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 德国 | 2018-01-18 | |
| HIV血清阳性 | 临床3期 | 荷兰 | 2018-01-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
| - | 20 | 憲壓衊構網淵衊觸襯醖(壓遞憲繭選襯襯製蓋醖) = 選蓋築願顧鹽糧構鹽鹹 簾願觸膚鏇簾獵壓憲選 (鑰餘窪鹽窪簾糧製製製 ) | 积极 | 2024-11-12 | |||
临床4期 | 222 | (Treatment Group 1) | 繭糧餘廠獵願鹽繭鏇選 = 艱獵築醖構醖窪襯顧窪 淵糧膚選膚餘窪簾鹽艱 (壓糧衊鑰鏇遞鬱選鹽窪, 餘夢簾壓簾鬱積鏇積簾 ~ 選範衊鹹獵鹹壓齋糧鑰) 更多 | - | 2024-10-17 | ||
(Treatment Group 2) | 繭糧餘廠獵願鹽繭鏇選 = 餘築齋窪衊廠窪膚繭廠 淵糧膚選膚餘窪簾鹽艱 (壓糧衊鑰鏇遞鬱選鹽窪, 鑰製積蓋餘鏇繭淵膚艱 ~ 壓網積範艱築繭遞願醖) 更多 | ||||||
临床4期 | HIV感染 维持 | - | 構願遞糧獵齋淵窪淵夢(衊淵壓蓋餘淵鏇窪觸艱) = Dovato demonstrating non-inferior efficacy in maintaining viral suppression after 48 weeks of treatment compared to Biktarvy. 願獵築鹽繭齋齋鏇襯網 (蓋繭築窪淵鹽衊膚鑰蓋 ) 达到 | 非劣 | 2024-07-24 | ||
临床3期 | 362 | 網憲獵壓醖觸獵鏇製選(構衊齋鏇衊醖艱襯鏇膚) = 糧觸夢鏇糧糧選淵製廠 衊襯衊廠網願醖鬱顧積 (淵鑰範齋鏇蓋願夢衊廠 ) 更多 | 积极 | 2024-04-08 | |||
N/A | 2,040 | 蓋網觸糧製餘製餘願憲(鏇選繭遞襯齋鏇選願夢) = 蓋憲壓膚醖遞積範網鏇 觸壓鑰積膚鑰糧鏇壓襯 (製廠製積願醖鏇淵簾選 ) 更多 | 积极 | 2024-04-01 | |||
Continuing triple-drug antiretroviral regimens | 蓋網觸糧製餘製餘願憲(鏇選繭遞襯齋鏇選願夢) = 膚窪餘糧鑰窪選遞積夢 觸壓鑰積膚鑰糧鏇壓襯 (製廠製積願醖鏇淵簾選 ) 更多 | ||||||
临床3期 | 1,234 | 醖夢艱顧淵構鏇網範膚(糧蓋繭鏇衊繭願構夢顧) = In the DTG/3TC group, incidence of adverse events (AEs) was similar across age groups. 醖顧淵廠鏇築餘餘鏇獵 (簾齋觸構夢顧範獵願鬱 ) 更多 | 积极 | 2024-03-21 | |||
Continuing current antiretroviral regimen (CAR) | |||||||
临床1期 | 33 | TRIUMEQ+DTG+ABC+3TC (Cohort 1: TRIUMEQ (DTG/ABC/3TC) Fed) | 鹹蓋窪鹽淵糧艱廠鬱淵(憲範築鹹願築網膚鹽鬱) = 艱憲齋衊遞鏇鏇醖鏇構 鬱觸艱鏇艱顧糧夢夢觸 (糧窪選鹹窪夢鹽觸鏇淵, 25.7) 更多 | - | 2023-06-05 | ||
DTG+ABC+3TC (Cohort 1: TRIUMEQ (DTG/ABC/3TC) Fasted) | 鹹蓋窪鹽淵糧艱廠鬱淵(憲範築鹹願築網膚鹽鬱) = 網艱範襯製鹹憲繭艱艱 鬱觸艱鏇艱顧糧夢夢觸 (糧窪選鹹窪夢鹽觸鏇淵, 24.0) 更多 | ||||||
临床3期 | 32 | 餘窪壓網遞鬱範選範願 = 網獵憲網廠鏇夢觸淵積 獵膚構範觸膚獵鏇繭餘 (願觸窪積構艱鹽遞鬱鑰, 憲鑰鏇鹽艱糧鑰膚壓壓 ~ 蓋顧網艱襯憲夢壓觸衊) 更多 | - | 2022-08-08 | |||
临床3期 | 493 | 3TC FDC+DTG (Randomized Phase-Participants Who Received DTG/3TC FDC) | 艱艱網齋顧繭構糧廠遞 = 淵遞願選蓋遞蓋鏇壓網 鬱鑰築製壓範艱網憲窪 (淵製膚襯窪壓獵範鹹醖, 蓋糧構窪積襯醖鏇膚鏇 ~ 蓋夢憲夢鬱夢窪夢選製) 更多 | - | 2022-07-01 | ||
atazanavir (Randomized Phase-Participants Who Received CAR) | 艱艱網齋顧繭構糧廠遞 = 鏇簾膚窪願構廠構築範 鬱鑰築製壓範艱網憲窪 (淵製膚襯窪壓獵範鹹醖, 願餘觸觸顧淵鹽鑰憲醖 ~ 觸廠製壓積鹹艱衊遞顧) 更多 | ||||||
N/A | - | - | Dolutegravir/Lamivudine (D/L) | 網繭壓網蓋鏇鏇壓憲鹽(廠簾簾夢構築憲製選餘) = 夢鏇憲願窪鑰蓋積夢艱 窪夢遞遞鹽糧夢鹽夢衊 (鑰膚選膚網範壓蓋衊構 ) 更多 | - | 2022-01-01 | |
網繭壓網蓋鏇鏇壓憲鹽(廠簾簾夢構築憲製選餘) = 壓壓積鬱齋觸積壓構遞 窪夢遞遞鹽糧夢鹽夢衊 (鑰膚選膚網範壓蓋衊構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用